<sup>123</sup>I‐2β‐carbomethoxy‐3β‐(4‐iodophenyl)‐<i>N</i>‐(3‐fluoropropyl) nortropane single photon emission computed tomography and <sup>123</sup>I‐metaiodobenzylguanidine myocardial scintigraphy in differentiating dementia with lewy bodies from other dementias: A comparative study

  • Pietro Tiraboschi
    Division of Neurology V/Neuropathology, Scientific Institute for Research, Hospitalization, and Care (IRCCS), Foundation “Carlo Besta” Neurological Institute Milan Italy
  • Angelo Corso
    Department of Nuclear Medicine Sant'Anna Hospital Como Italy
  • Ugo Paolo Guerra
    Department of Nuclear Medicine Poliambulanza Foundation Brescia Italy
  • Flavio Nobili
    Department of Neuroscience University of Genoa Genoa Italy
  • Arnoldo Piccardo
    Nuclear Medicine Unit, Department of Diagnostic Imaging E. O. Galliera Hospital Genoa Italy
  • Maria Lucia Calcagni
    Institute of Nuclear Medicine Catholic University of the Sacred Heart Rome Italy
  • Duccio Volterrani
    Nuclear Medicine Unit University Hospital of Pisa Pisa Italy
  • Diego Cecchin
    Department of Medicine University of Padua Padua Italy
  • Mauro Tettamanti
    Laboratory of Geriatric Neuropsychiatry, Institute of Hospitalization and Scientific Care Mario Negri Institute of Pharmacological Research Milan Italy
  • Luigi Antelmi
    Health Department, Institute of Hospitalization and Scientific Care Foundation Carlo Besta Neurological Institute Milan Italy
  • Simone Vidale
    Department of Neurology and Stroke Unit Sant'Anna Hospital Como Italy
  • Leonardo Sacco
    Department of Neurology and Stroke Unit Sant'Anna Hospital Como Italy
  • Maria Merello
    European Foundation for Biomedical Research, Alzheimer Center of Excellence, Briolini Hospital of Gazzaniga Bergamo Italy
  • Stefano Stefanini
    European Foundation for Biomedical Research, Alzheimer Center of Excellence, Briolini Hospital of Gazzaniga Bergamo Italy
  • Anna Micheli
    Neurology Unit, San Francesco Clinic Bergamo Italy
  • Paola Vai
    Department of Nuclear Medicine Papa Giovanni XXIII Hospital Bergamo Italy
  • Selene Capitanio
    Department of Nuclear Medicine Papa Giovanni XXIII Hospital Bergamo Italy
  • Sara Vincenzina Gabanelli
    Department of Nuclear Medicine Papa Giovanni XXIII Hospital Bergamo Italy
  • Riccardo Riva
    Department of Neurology Papa Giovanni XXIII Hospital Bergamo Italy
  • Patrizia Pinto
    Department of Neurology Papa Giovanni XXIII Hospital Bergamo Italy
  • Ave Maria Biffi
    Department of Psychology Papa Giovanni XXIII Hospital Bergamo Italy
  • Cristina Muscio
    Division of Neurology V/Neuropathology, Scientific Institute for Research, Hospitalization, and Care (IRCCS), Foundation “Carlo Besta” Neurological Institute Milan Italy

抄録

<jats:sec><jats:title>Objective</jats:title><jats:p>To compare the diagnostic value of striatal <jats:sup>123</jats:sup>I‐2β‐carbomethoxy‐3β‐(4‐iodophenyl)‐<jats:italic>N</jats:italic>‐(3‐fluoropropyl) nortropane (<jats:sup>123</jats:sup>I‐FP‐CIT) single photon emission computed tomography (SPECT) and <jats:sup>123</jats:sup>I‐metaiodobenzylguanidine (<jats:sup>123</jats:sup>I‐MIBG) myocardial scintigraphy in differentiating dementia with Lewy bodies (DLB) from other dementia types.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>This prospective longitudinal study included 30 patients with a clinical diagnosis of DLB and 29 patients with non‐DLB dementia (Alzheimer disease, n = 16; behavioral variant frontotemporal dementia, n = 13). All patients underwent <jats:sup>123</jats:sup>I‐FP‐CIT SPECT and <jats:sup>123</jats:sup>I‐MIBG myocardial scintigraphy within a few weeks of clinical diagnosis. All diagnoses at each center were agreed upon by the local clinician and an independent expert, both unaware of imaging data, and re‐evaluated after 12 months. Each image was visually classified as either normal or abnormal by 3 independent nuclear physicians blinded to patients' clinical data.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Overall, sensitivity and specificity to DLB were respectively 93% and 100% for <jats:sup>123</jats:sup>I‐MIBG myocardial scintigraphy, and 90% and 76% for <jats:sup>123</jats:sup>I‐FP‐CIT SPECT. Lower specificity of striatal compared to myocardial imaging was due to decreased <jats:sup>123</jats:sup>I‐FP‐CIT uptake in 7 non‐DLB subjects (3 with concomitant parkinsonism) who had normal <jats:sup>123</jats:sup>I‐MIBG myocardial uptake. Notably, in our non‐DLB group, myocardial imaging gave no false‐positive readings even in those subjects (n = 7) with concurrent medical illnesses (diabetes and/or heart disease) supposed to potentially interfere with <jats:sup>123</jats:sup>I‐MIBG uptake.</jats:p></jats:sec><jats:sec><jats:title>Interpretation</jats:title><jats:p><jats:sup>123</jats:sup>I‐FP‐CIT SPECT and <jats:sup>123</jats:sup>I‐MIBG myocardial scintigraphy have similar sensitivity for detecting DLB, but the latter appears to be more specific for excluding non‐DLB dementias, especially when parkinsonism is the only “core feature” exhibited by the patient. Our data also indicate that the potential confounding effects of diabetes and heart disease on <jats:sup>123</jats:sup>I‐MIBG myocardial scintigraphy results might have been overestimated. Ann Neurol 2016;80:368–378</jats:p></jats:sec>

収録刊行物

被引用文献 (3)*注記

もっと見る

問題の指摘

ページトップへ